{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:54:26Z","timestamp":1783691666922,"version":"3.55.0"},"reference-count":37,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite the widespread application of next-generation sequencing (NGS) in advanced lung adenocarcinoma, its impact on survival and the optimal timing for the examination remain uncertain. This cohort study included advanced lung adenocarcinoma patients who underwent NGS testing. We categorized patients into four groups: Group 1: treatment-na\u00efve, upfront NGS; Group 2: Treatment-na\u00efve, exclusionary EGFR\/ALK\/ROS1; Group 3: post-treatment, no known EGFR\/ALK\/ROS1; Group 4: known driver mutation and post-TKI treatment. A total of 424 patients were included. There were 128, 126, 90, and 80 patients in Groups 1, 2, 3, and 4, respectively. In Groups 1, 2, 3, and 4, targetable mutations were identified in 76.6%, 49.2%, 41.1%, and 33.3% of the patients, respectively (p &lt; 0.001). Mutation-targeted treatments were applied in 68.0%, 15.1%, 27.8%, and 22.5% of the patients, respectively (p &lt; 0.001). In the overall population, patients receiving mutation-targeted treatments exhibited significantly longer overall survival (OS) (aHR 0.54 [95% CI 0.37\u20130.79], p = 0.001). The most profound benefit was seen in the Group 1 patients (not reached vs. 40.4 months, p = 0.028). The median OS of patients with mutation-targeted treatments was also significantly longer among Group 2 patients. The median post-NGS survival of patients receiving mutation-targeted treatments was numerically longer in Group 3 and Group 4 patients. In conclusion, mutation-targeted therapy is associated with a favorable outcome. However, the opportunities of NGS-directed treatment and the survival benefits of mutation-targeted treatment were various among different populations.<\/jats:p>","DOI":"10.3390\/ijms25136949","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T05:11:39Z","timestamp":1719465099000},"page":"6949","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination"],"prefix":"10.3390","volume":"25","author":[{"given":"Po-Hsin","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan"},{"name":"Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan"},{"name":"Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung 402, Taiwan"},{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Fan","family":"Ou","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hsiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan"},{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan"},{"name":"Lung Cancer Comprehensive Care and Research Center, Taichung Veterans General Hospital, Taichung 407, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-904X","authenticated-orcid":false,"given":"Kuo-Hsuan","family":"Hsu","sequence":"additional","affiliation":[{"name":"Lung Cancer Comprehensive Care and Research Center, Taichung Veterans General Hospital, Taichung 407, Taiwan"},{"name":"Division of Critical Care and Respiratory Therapy, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-4495","authenticated-orcid":false,"given":"Jeng-Sen","family":"Tseng","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan"},{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan"},{"name":"Lung Cancer Comprehensive Care and Research Center, Taichung Veterans General Hospital, Taichung 407, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-417X","authenticated-orcid":false,"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan"},{"name":"School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan"},{"name":"Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0198-1077","authenticated-orcid":false,"given":"Tsung-Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan"},{"name":"Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan"},{"name":"Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung 402, Taiwan"},{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan"},{"name":"Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae Insights: Non\u2013Small Cell Lung Cancer, Version 2.2023: Featured updates to the NCCN guidelines","volume":"21","author":"Ettinger","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2200715","DOI":"10.1200\/PO.22.00715","article-title":"Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer","volume":"7","author":"Gibbs","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.32503","article-title":"Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer","volume":"126","author":"Papadimitrakopoulou","year":"2020","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/PO.20.00048","article-title":"Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology","volume":"4","author":"Hsiao","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102029","DOI":"10.1016\/j.eclinm.2023.102029","article-title":"Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: An observational study on the impact of selection based on clinical judgement","volume":"60","author":"Colomer","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102200","DOI":"10.1016\/j.esmoop.2023.102200","article-title":"Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: A population-based registry study","volume":"9","author":"Kang","year":"2024","journal-title":"ESMO Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2147\/CMAR.S436808","article-title":"The Prognosis of Advanced Non-Small Cell Lung Cancer Patients with Precision-Targeted Therapy Guided by NGS Testing or Routine Testing","volume":"15","author":"Tu","year":"2023","journal-title":"Cancer Manag. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hsu, K.H., Ho, C.C., Hsia, T.C., Tseng, J.S., Su, K.Y., Wu, M.F., Chiu, K.L., Yang, T.Y., Chen, K.C., and Ooi, H. (2015). Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120852"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jtho.2016.08.142","article-title":"Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma","volume":"11","author":"Li","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jtho.2022.10.021","article-title":"Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in Asia","volume":"18","author":"Mitsudomi","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1556-0864(15)30353-1","article-title":"Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients","volume":"1","author":"Chang","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/crj.13472","article-title":"Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions","volume":"16","author":"Liu","year":"2022","journal-title":"Clin. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40169-017-0135-8","article-title":"Tissue is the issue and tissue competition. Re-biopsy for mutation T790: Where and why?","volume":"6","author":"Zarogoulidis","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.21037\/tlcr.2019.09.15","article-title":"Role of liquid biopsy in oncogene-addicted non-small cell lung cancer","volume":"8","author":"Canale","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ulivi, P., Urini, M., Petracci, E., Canale, M., Dubini, A., Bartolini, D., Calistri, D., Cravero, P., Fonzi, E., and Martinelli, G. (2022). Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients. Cancers, 14.","DOI":"10.3390\/cancers14102352"},{"key":"ref_27","unstructured":"Roche Molecular Systems, Inc. (2024, May 24). cobas EGFR Mutation Test v2, Available online: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf12\/P120019S007c.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.21873\/anticanres.16445","article-title":"Possible False Results With cobas((R)) EGFR Mutation Test v2 and Oncomine Dx Target Test for EGFR Mutation","volume":"43","author":"Kanaoka","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13566","DOI":"10.1038\/s41598-022-17394-7","article-title":"Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer","volume":"12","author":"Shen","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/1878-0261.13327","article-title":"Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets","volume":"17","author":"Viteri","year":"2023","journal-title":"Mol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S9021","DOI":"10.1200\/JCO.2023.41.16_suppl.9021","article-title":"Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib","volume":"41","author":"Tan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S1670","DOI":"10.1016\/j.annonc.2023.10.594","article-title":"Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates","volume":"34","author":"Horinouchi","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jtho.2020.10.155","article-title":"Lung Cancer in Republic of China","volume":"16","author":"Luo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.cllc.2022.06.007","article-title":"Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles","volume":"23","author":"Hsu","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"ref_37","unstructured":"Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., and Sullivan, D.C. (2018). AJCC Cancer Staging Manual, Springer. [8th ed.]."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/6949\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:04:14Z","timestamp":1760108654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/6949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":37,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25136949"],"URL":"https:\/\/doi.org\/10.3390\/ijms25136949","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}